Laurus Labs

Price chart

Previous close

₹2,370.00

Open

₹2,359.70

Day high

₹2,480.00

Day low

₹2,351.50

Listed on NSE since 19 December 2016.

Futures and options

Futures, 23 Nov expiry

₹2,433.30

Premium to the share price

+6.80 (+0.28%)

Futures open interest

41,733 contracts (+740 today)

Lot size (NOV 26)

425 shares

Source: NSE, 09-Nov-2026 12:05:17, delayed. Option chain · All futures · Lot sizes

Pivot levels

R3

2,383.70

R2

2,362.60

R1

2,351.30

CPR top

2,335.10

Pivot

2,330.20

CPR bottom

2,325.30

S1

2,318.90

S2

2,297.80

S3

2,286.50

From Friday 6 November’s high, low and close (Yahoo Finance). Arithmetic on past prices, not a forecast.

Market value

₹1,26,433 Cr

P/E (trailing)

94.43

EPS (trailing)

₹24.78

Price to book

20.86

Dividend yield

0.09%

Return on equity

24.0%

Debt to equity

0.42

Profit margin

17.1%

Beta

0.22

Volume today

29.05 L

Average volume

24.52 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Laurus Labs’s results filed with NSE, consolidated (the whole group). Net profit is the share of Laurus Labs’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Laurus Labs’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Industry

Drug Manufacturers - Specialty & Generic

Based in

Hyderabad

Employees

7,059

Company website · Profile: Yahoo Finance

No headlines name Laurus Labs in the last day or two.

• Interim Dividend - Re 1 Per Share

  Dividend · ex-date 6 November 2026

• Interim Dividend - Rs 1.20 Per Share

  Dividend · ex-date 8 May 2026

• Interim Dividend - Re 0.80 Per Sh

  Dividend · ex-date 31 October 2025

• Interim Dividend - Rs 0.80 Per Share

  Dividend · ex-date 9 May 2025

• Interim Dividend - Rs 0.40 Per Share

  Dividend · ex-date 6 November 2024

• Annual General Meeting

  Action · ex-date 4 July 2024

• Interim Dividend - Re 0.40 Per Share

  Dividend · ex-date 8 May 2024

• Interim Dividend - Re 0.40 Per Share

  Dividend · ex-date 2 November 2023

Source: NSE. Latest first, 8 of 20.